Suchergebnisse - "Lunceford, Jared"

PubPharm (82)

1

Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer

enthalten in: Gynecologic oncology | 2024

von Wehn, A. | Qiu, P. | Lunceford, J. | +9

2

BIOMARKERS FOR PREDICTING ELIGIBILITY FOR AN ANTI-ILT4 AND ANTI-PD-1 COMBINATION THERAPY

enthalten in: Europäisches Patentamt | 2023

von ALTURA RACHEL | LUNCEFORD JARED | MARKENSOHN JULIA | +2

3

Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer : KEYNOTE-086 Exploratory Analysis

enthalten in: JCO precision oncology | 2023

von Loi, S. | Salgado, R. | Schmid, P. | +20

4

Biomarkers predictive of response to pembrolizumab in head and neck cancer

enthalten in: Cancer medicine | 2023

von Pfister, D. | Haddad, R. | Worden, F. | +19

5

SYSTEM AND METHODS FOR DERIVING GENE SIGNATURE BIOMARKERS OF RESPONSE TO PD-1 ANTAGONISTS

enthalten in: Europäisches Patentamt | 2023

von AYERS MARK D | LOBODA ANDREY | LUNCEFORD JARED K | +3

6

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

enthalten in: JTO clinical and research reports | 2023

von Garassino, M. | Gadgeel, S. | Novello, S. | +18

7

Biomarkers predictive of response to pembrolizumab in head and neck cancer

enthalten in: Cancer Medicine | 2023

von Pfister, D. | Haddad, R. | Worden, F. | +19

8

Correction : First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Siu, L. | Wang, D. | Hilton, J. | +11

ErratumFor: Clin Cancer Res. 2022 Jan 1;28(1):57-70. - PMID 34598945

9

T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer

enthalten in: Future oncology (London, England) | 2022

von Shah, M. | Kojima, T. | Hochhauser, D. | +18

10

System and methods for deriving gene signature biomarkers of response to PD-1 antagonists

enthalten in: Europäisches Patentamt | 2022

von AYERS MARK D | LOBODA ANDREY | LUNCEFORD JARED K | +3

1
2
3
4
5
6
7
8
9
Nächster »
[9]